Search
Feedback
About UniCat 
Help
News
| Listing 1 - 4 of 4 |
Sort by
|
Book
ISBN: 3318072125 3318070750 Year: 2023 Publisher: Oxford, UK : S. Karger AG,
Abstract | Keywords | Export | Availability | Bookmark
Loading...Choose an application
- Reference Manager
- EndNote
- RefWorks (Direct export to RefWorks)
Identifying tumor-specific molecular aberrations via molecular profiling is vital for the use of targeted therapies. Understanding a patient's unique tumor genetics provides predictive and prognostic information that enables a personalized care plan to be put in place, improving outcomes and minimizing ineffective treatments. 'Fast Facts: Molecular Profiling in Solid Tumors' provides a firm knowledge foundation of somatic molecular profiling methodologies, key information to help with the use of molecular profiling in daily practice and advice on communicating with patients about molecular testing and results.
Book
ISBN: 9783318072129 9783318070750 Year: 2023 Publisher: Basel S. Karger
Abstract | Keywords | Export | Availability | Bookmark
Loading...Choose an application
- Reference Manager
- EndNote
- RefWorks (Direct export to RefWorks)
Multi
ISBN: 9783318072129 9783318070750 Year: 2023 Publisher: Basel S. Karger
Abstract | Keywords | Export | Availability | Bookmark
Loading...Choose an application
- Reference Manager
- EndNote
- RefWorks (Direct export to RefWorks)
Identifying tumor-specific molecular aberrations via molecular profiling is vital for the use of targeted therapies. Understanding a patient's unique tumor genetics provides predictive and prognostic information that enables a personalized care plan to be put in place, improving outcomes and minimizing ineffective treatments. 'Fast Facts: Molecular Profiling in Solid Tumors' provides a firm knowledge foundation of somatic molecular profiling methodologies, key information to help with the use of molecular profiling in daily practice and advice on communicating with patients about molecular testing and results.Table of Contents:• Molecular profiling: the basics• Rationale for testing• Sample collection• Test selection and process• Interpreting the report• Talking to patients• Challenges and opportunities
Book
ISBN: 3318071366 3318070203 Year: 2022 Publisher: Abingdon, Oxford : S. Karger AG,
Abstract | Keywords | Export | Availability | Bookmark
Loading...Choose an application
- Reference Manager
- EndNote
- RefWorks (Direct export to RefWorks)
Lung cancer is still a major cause of death globally, but the development of personalized, precision medicine has had a marked effect on treatment management and improved clinical outcomes, particularly for those with advanced stage non-small-cell lung cancer (NSCLC). EGFR mutations are the third most common mutation found in patients with advanced stage NSCLC. First-line treatment with a traditional epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is indicated for most patients, but not for patients with EGFR exon 20 insertion mutations (ex20ins). Instead, recent approvals of an EGFR ex20ins-specific TKI (mobocertinib) and a bispecific antibody (amivantamab) targeting both EGFR and mesenchymalepithelial transition factor (MET) offer the potential for improved outcomes in this patient population. Furthermore, new approaches to treatment continue to be developed and trials for new agents with greater activity against ex20ins mutations are ongoing.
Epidermal growth factor. --- Lungs --- Cancer --- Genetic aspects. --- Anthelone --- EGF (Growth factor) --- EGF-URO (Growth factor) --- EGF-Urogastrone --- Epidermal growth factor-Urogastrone --- Uroanthelone --- Uroenterone --- Growth factors
| Listing 1 - 4 of 4 |
Sort by
|